PEORIA, Ill. — Veloxity Labs, a bioanalytical contract research organization (CRO) focused on accelerating programs with speed and precision, announced the acquisition of the ZenoTOF 8600 system from SCIEX, a global leader in life science analytical technologies. Veloxity becomes the first bioanalytical CRO in the United States to bring the ZenoTOF 8600 accurate mass spectrometer online, with delivery expected later this year and installation and qualification beginning in January 2026.
The addition of the ZenoTOF 8600 system expands Veloxity’s analytical capabilities for peptide and protein bioanalysis, enhancing method development speed, identity confirmation, and interference resolution while complementing its existing LC–MS/MS triple quadrupole platforms. The investment also aligns with Veloxity’s ongoing laboratory expansion, which includes plans for an additional instrument lab, increased freezer capacity, and team growth later this year—signaling both long-term stability and near-term capacity for sponsors advancing GLP-enabling and Phase 1/2 studies.
“Adding the ZenoTOF 8600 system gives our scientists a faster, more selective way to solve hard problems, especially in peptide and complex matrix workflows,” said Shane Needham, Ph.D., Co-Founder, President, and CEO of Veloxity Labs. “We’re investing in innovation that will create an immediate impact on sponsor timelines: quicker method cycles, better tools to handle interferences, and added sensitivity headroom for GLP-1 receptor agonists and other peptides. It’s a natural fit with our model of speed with purpose and our growth in capacity.”
The ZenoTOF 8600 system provides several key advantages for Veloxity’s sponsors. Its high-resolution accurate mass (HRAM) capabilities deliver superior selectivity and sensitivity across an expanded mass range, enabling faster method setup and refinement for intact peptides and proteins—even at low concentrations and small sample volumes. The technology enhances confidence in complex biological matrices through improved interference deconvolution and confirmation and complements existing triple-quadrupole systems by offering a high-selectivity pathway that can shorten overall development cycles for complex modalities.
“We’re excited to support Veloxity’s early adoption of the ZenoTOF 8600 system,” said Jose Castro-Perez, Vice President of Product Management at SCIEX. “HRAM technology helps labs confirm identity, resolve challenging interferences, and advance sensitive workflows—capabilities that matter for today’s peptide-rich pipelines. Veloxity’s focus on efficiency and scientific rigor makes them an ideal partner to showcase what the ZenoTOF 8600 system can unlock.”
By integrating the ZenoTOF 8600 system into its workflow, Veloxity Labs continues to strengthen its position as a leading partner for peptide, protein, and complex bioanalytical programs, combining cutting-edge instrumentation with rapid, science-driven execution.
